Amicus Therapeutics Inc

-0.02 (-0.26%)
Earnings Announcements

Amicus Therapeutics Q1 Loss Per Share $0.30

Published: 05/09/2022 13:46 GMT
Amicus Therapeutics Inc (FOLD) - Amicus Therapeutics Announces First Quarter 2022 Financial Results.
Q1 Loss per Share $0.30.
Q1 Revenue Rose 18.5 Percent to $78.7 Million.
Q1 Earnings per Share View $-0.26, Revenue View $77.1 Million -- Refinitiv Ibes Data (analyst estimates).
For Full-year 2022, Company Anticipates Total Galafold Revenue of $350 Million to $365 Million at Constant Exchange Rates.
Cash, Cash Equivalents, and Marketable Securities Totaled $411.2 Million at March 31, 2022.
Amicus Therapeutics - Based on Current Operating Models, Co Believes Current and Projected Cash Flows Are Sufficient to Achieve Self-sustainability.
Revenue is expected to be $86.61 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $91.37 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.